Market Trends J&J boasts Rybrevant, Lazcluze combo bests AstraZeneca’s TagrissoBy admin8996erT0allMarch 26, 2025 yuelan Johnson & Johnson (NYSE:JNJ) said that data from a phase 3 trial indicated that a combination of Rybrevant (amivantamab)…
